Associated Papers
Structural insights into the substrate uptake and inhibition of the human creatine transporter (hCRT).
Yuan X et al.
Proceedings of the National Academy of Sciences of the United States of America, 2025
Dopamine Transporter Deficiency Syndrome: A Rare Case of Infantile-Onset Dystonia-Parkinsonism.
Madduluri B et al.
Journal of Movement Disorders, 2025
40262646 (PubMed )
Supplement: jmd-25057-Supplementary-Table-1.pdf
Dopamine Transporter Deficiency Syndrome (DTDS): Expanding the Clinical Phenotype and Precision Medicine Approaches.
Ng J et al.
Cells, 2023
The dopamine transporter gene SLC6A3: multidisease risks.
Reith MEA et al.
Molecular Psychiatry, 2022
Tropane-Based Ibogaine Analog Rescues Folding-Deficient Serotonin and Dopamine Transporters.
Bhat S et al.
Acs Pharmacology & Translational Science, 2021
The Creatine Transporter Unfolded: A Knotty Premise in the Cerebral Creatine Deficiency Syndrome.
Farr CV et al.
Frontiers in Synaptic Neuroscience, 2020
SLC6 Transporter Folding Diseases and Pharmacochaperoning.
Freissmuth M et al.
Handbook of Experimental Pharmacology, 2018
Pharmacochaperoning in a Drosophila model system rescues human dopamine transporter variants associated with infantile/juvenile parkinsonism.
Asjad HMM et al.
The Journal of Biological Chemistry, 2017
A Caenorhabditis elegans model to study dopamine transporter deficiency syndrome.
Illiano P et al.
The European Journal of Neuroscience, 2017
Genetic targeting of the amphetamine and methylphenidate-sensitive dopamine transporter: on the path to an animal model of attention-deficit hyperactivity disorder.
Mergy MA et al.
Neurochemistry International, 2014
Defining the blanks--pharmacochaperoning of SLC6 transporters and ABC transporters.
Chiba P et al.
Pharmacological Research, 2014
Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study.
Kurian MA et al.
The Lancet. Neurology, 2011
Select a paper to view details